Most Recent
Hitting back at claims that its App Store stifles competition, Apple has told a trial that app developers have myriad ways of maximising profits without paying it a commission, noting Epic Games made US$3.8 billion from in-game currency V-Bucks in 2021.
A five-year-old class action against BHP over the collapse of a Brazilian dam is seeking to amend the group definition following a judgment limiting the class size, but the mining company says it should not be punished for the applicant’s pleading mistake.
A former EY partner is trying again to keep their identity secret in proceedings brought by the Tax Office alleging they promoted tax exploitation schemes.
Westpac subsidiary BT Funds Management and Tal Life Insurance have foreshadowed applications to strike out the pleadings of a class action alleging superannuation customers were overcharged for insurance coverage.
The lead plaintiff and several group members in a class action against the Australian Football League on behalf of players who allegedly suffered brain injuries have “very strong” opposition to adding individual clubs, a court has heard.
A judge has dismissed the corporate regulator’s first-ever case over unfair insurance contracts terms, finding it was not unfair for an insurer to require customers to notify it if anything changed about their home or its contents.
The Australian Securities and Investments Commission has won an interim travel ban against the CEO of software company Dubber Corporation and its external solicitor in Melbourne, with the regulator saying it suspects misuse of term deposit funds.
Hells Angels has asked the High Court to reinstate an award of $78,000 for online marketplace Redbubble's infringement of its trade marks, after the Full Court found it was owed just $100 in nominal damages.
Investors in an apartment development in Melbourne have brought a class action against the responsible managers for two managed investment schemes, alleging their funds were misused.
Indian generics company Sun Pharma has taken Otsuka Pharmaceutical to court, alleging an extension for the patent for an injectable form of the Japanese drug maker's blockbuster antipsychotic Abilify was wrongly granted and should be invalidated.